دورية أكاديمية

Clinical and neurochemical correlates of the APOE genotype in early-stage Parkinson's disease.

التفاصيل البيبلوغرافية
العنوان: Clinical and neurochemical correlates of the APOE genotype in early-stage Parkinson's disease.
المؤلفون: Zenuni, Henri1 (AUTHOR), Bovenzi, Roberta1 (AUTHOR), Bissacco, Jacopo1 (AUTHOR), Grillo, Piergiorgio1 (AUTHOR), Simonetta, Clara1 (AUTHOR), Mascioli, Davide1 (AUTHOR), Pieri, Massimo2 (AUTHOR), Bernardini, Segio2 (AUTHOR), Sancesario, Giulia Maria3 (AUTHOR), Stefani, Alessandro1 (AUTHOR), Mercuri, Nicola Biagio1 (AUTHOR), Schirinzi, Tommaso1 (AUTHOR) t.schirinzi@yahoo.com
المصدر: Neurobiology of Aging. Nov2023, Vol. 131, p24-28. 5p.
مصطلحات موضوعية: *PARKINSON'S disease, *APOLIPOPROTEIN E, *TAU proteins, *GENOTYPES, *CEREBROSPINAL fluid
مستخلص: Emerging evidence indicates that apolipoprotein E (APOE) genotype may influence Parkinson's disease (PD) course, although clinical and neurochemical correlates have not been completely established. This study aimed to determine the associations of APOE genotypes (ε4 vs. non-ε4) with cerebrospinal fluid (CSF) neurodegeneration biomarkers and clinical parameters in early-stage PD patients. One hundred and seventy-five PD patients and 89 non-neurodegenerative controls grouped in APOE- ε4 carriers (28 PD; 12 controls) and non- APOE -ε4 carriers (147 PD; 78 controls) were enrolled. CSF levels of amyloid-β-42, amyloid-β-40, total and 181-phosphorylated tau, and clinical scores were compared among groups adjusting for main covariates. APOE genotypes prevalence was similar in PD and controls. PD APOE -ε4 carriers had lower amyloid-β-42 CSF levels than PD non- APOE -ε4 carriers and controls, independently from age. PD APOE -ε4 carriers also had higher total and "item 5" (attention and memory) non-motor symptoms scale scores than PD non- APOE -ε4 carriers, independently from confounding factors. APOE -ε4 genotype might thus account for a more vulnerable PD subtype characterized by prominent amyloidopathy and a greater burden of non-motor symptoms in the early disease stages. Data are available upon reasonable request. [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:01974580
DOI:10.1016/j.neurobiolaging.2023.07.011